Overview

Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer

Status:
Active, not recruiting

Trial end date:
2022-12-01

Target enrollment:

Participant gender:

Summary

This is a randomized phase 2 trial of gemcitabine + carboplatin + nivolumab or gemcitabine + oxaliplatin + nivolumab for the treatment of cisplatin-ineligible patients with metastatic urothelial cancer. Randomization will be stratified on the lymph node only (and/or unresectable primary) metastatic status.

Phase:

Phase 2

Details

Lead Sponsor:

Matthew Galsky

Collaborators:

Bristol-Myers Squibb
Hoosier Cancer Research Network

Treatments:

Antibodies, Monoclonal
Carboplatin
Cisplatin
Gemcitabine
Nivolumab
Oxaliplatin